Enantioselective process for cycloalkenyl β-substituted alanines
申请人:Liu Zijun
公开号:US08558023B2
公开(公告)日:2013-10-15
A process for preparing an enantiomerically enriched cycloalkene-substituted alanine compound having the structure:
by asymmetrically hydrogenating a dehydro amino acid compound having the structure:
in a suitable reaction media in the presence of a catalyst having a transition metal moiety complexed to a chiral phosphine ligand to prepare enantiomerically enriched cycloalkene substituted alanine compounds having the structure of Formula (IA) or (IB), which are key intermediates for the ACE inhibitors ramipril and perindolpril:
AN ENANTIOSELECTIVE PROCESS FOR CYCLOALKENYL B-SUBSTITUTED ALANINES
申请人:Chiral Quest, Inc.
公开号:EP2560493B1
公开(公告)日:2018-06-06
US8558023B2
申请人:——
公开号:US8558023B2
公开(公告)日:2013-10-15
[EN] AN ENANTIOSELECTIVE PROCESS FOR CYCLOALKENYL B-SUBSTITUTED ALANINES<br/>[FR] PROCÉDÉ ÉNANTIOSÉLECTIF DE PRODUCTION DE CYCLOALCÉNYLALANINES BÊTA-SUBSTITUÉES
申请人:CHIRAL QUEST INC
公开号:WO2011133651A1
公开(公告)日:2011-10-27
A process for preparing an enantiomerically enriched cycloalkene- substituted alanine compound having the structure:Formule (I) by asymmetrically hydrogenating a dehydro amino acid compound having the structure: Formula (V) in a suitable reaction media in the presence of a catalyst having a transition metal moiety complexed to a chiral phosphine ligand to prepare enantiomerically enriched cycloalkene substituted alanine compounds having the structure of Formula (IA) or (IB), which are key intermediates for the ACE inhibitors ramipril and perindolpril: Formula (IA) Formula (IB)
ENANTIOSELECTIVE PROCESS FOR CYCLOALKENYL ?-SUBSTITUTED ALANINES
申请人:Liu Zijun
公开号:US20110257408A1
公开(公告)日:2011-10-20
A process for preparing an enantiomerically enriched cycloalkene-substituted alanine compound having the structure:
by asymmetrically hydrogenating a dehydro amino acid compound having the structure:
in a suitable reaction media in the presence of a catalyst having a transition metal moiety complexed to a chiral phosphine ligand to prepare enantiomerically enriched cycloalkene substituted alanine compounds having the structure of Formula (IA) or (IB), which are key intermediates for the ACE inhibitors ramipril and perindolpril: